Search results for "Virus"

showing 10 items of 5024 documents

Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe

2018

Abstract: Hepatitis C virus (HCV) infection is a major public health problem in the European Union (EU). An estimated 5.6 million Europeans are chronically infected with a wide range of variation in prevalence across European Union countries. Although HCV continues to spread as a largely silent pandemic, its elimination is made possible through the availability of the new antiviral drugs and the implementation of prevention practices. On 17 February 2016, the Hepatitis B & C Public Policy Association held the first EU HCV Policy Summit in Brussels. This summit was an historic event as it was the first high-level conference focusing on the elimination of HCV at the European Union level. The …

medicine.medical_specialtyCivil societyEconomic growthMedizinPublic policyHepacivirusAntiviral AgentsPatient advocacy03 medical and health sciences0302 clinical medicineVirologyPolitical sciencePandemicPrevalencemedicineHumansmedia_common.cataloged_instanceEuropean Union030212 general & internal medicineDisease EradicationEuropean unionmedia_commongeographySummitgeography.geographical_feature_categoryHepatologyPublic healthmedicine.diseaseHepatitis CEuropeInfectious DiseasesHCVEpidemiological Monitoring030211 gastroenterology & hepatologyHuman medicineViral hepatitisJournal of Viral Hepatitis
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct

Outcomes of hospitalized patients with COVID-19 according to level of frailty

2021

Background The complications from coronavirus disease 2019 (COVID-19) have been the subject of study in diverse scientific reports. However, many aspects that influence the prognosis of the disease are still unknown, such as frailty, which inherently reduces resistance to disease and makes people more vulnerable. This study aimed to explore the complications of COVID-19 in patients admitted to a third-level hospital and to evaluate the relationship between these complications and frailty. Methods An observational, descriptive, prospective study was performed in 2020. A sample of 254 patients from a database of 3,112 patients admitted to a high-level hospital in Madrid, Spain was analyzed. …

medicine.medical_specialtyComplicationsCoronavirus disease 2019 (COVID-19)lcsh:MedicineDiseaseGeneral Biochemistry Genetics and Molecular Biologylaw.invention03 medical and health sciences0302 clinical medicinelawStatistical significanceInternal MedicinemedicineCoronavirus infection030212 general & internal medicineMortalityProspective cohort studyAgedFrailtybusiness.industrySARS-CoV-2General NeuroscienceMortality ratelcsh:RCOVID-19General MedicinePrognosisIntensive care unitGeriatricsEmergency medicineDeliriumObservational studyPublic Healthmedicine.symptomGeneral Agricultural and Biological Sciencesbusiness030217 neurology & neurosurgery
researchProduct

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the …

2018

Summary Cytomegalovirus is one of the most important infections to occur after allogeneic haematopoietic stem cell transplantation (HSCT), and an increasing number of reports indicate that cytomegalovirus is also a potentially important pathogen in patients treated with recently introduced drugs for hematological malignancies. Expert recommendations have been produced by the 2017 European Conference on Infections in Leukaemia (ECIL 7) after a review of the literature on the diagnosis and management of cytomegalovirus in patients after HSCT and in patients receiving other types of therapy for haematological malignancies. These recommendations cover diagnosis, preventive strategies such as pr…

medicine.medical_specialtyCongenital cytomegalovirus infectionCytomegalovirusAntiviral AgentsLetermovirInternal medicinemedicineHumansIn patientGanciclovirLeukemiabusiness.industryHematopoietic Stem Cell TransplantationMaribavirmedicine.diseaseTransplantationClinical trialHaematopoiesisInfectious DiseasesHematologic NeoplasmsCytomegalovirus InfectionsPractice Guidelines as TopicBenzimidazolesRibonucleosidesStem cellbusinessmedicine.drugThe Lancet. Infectious diseases
researchProduct

Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.

2016

Cytomegalovirus (CMV) infection remains a major complication of solid organ transplantation. Because of management of CMV is variable among transplant centers, in 2011 the Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) developed consensus guidelines for the prevention and treatment of CMV infection in solid organ transplant recipients. Since then, new publications have clarified or questioned the aspects covered in the previous document. For that reason, a panel of experts revised the evidence on CMV management, including immunological monitoring, diagnostics, prevention, vaccines, indirect effects, tre…

medicine.medical_specialtyCongenital cytomegalovirus infectionMEDLINEDrug resistance030230 surgeryAntiviral AgentsOrgan transplantation03 medical and health sciences0302 clinical medicineMonitoring ImmunologicMedicineHumansMajor complicationIntensive care medicineTransplantationbusiness.industryOrgan Transplantationmedicine.diseaseTransplant RecipientsCytomegalovirus infectionClinical microbiologyImmunologyCytomegalovirus InfectionsPractice Guidelines as Topic030211 gastroenterology & hepatologybusinessSolid organ transplantationTransplantation reviews (Orlando, Fla.)
researchProduct

Recommendations for ophthalmologic practice during the easing of COVID‐19 control measures

2021

Abstract In the context of the COVID‐19 pandemic, this paper provides recommendations for medical eye care during the easing of control measures after lockdown. The guidelines presented are based on a literature review and consensus among all Spanish Ophthalmology Societies regarding protection measures recommended for the ophthalmologic care of patients with or without confirmed COVID‐19 in outpatient, inpatient, emergency and surgery settings. We recommend that all measures be adapted to the circumstances and availability of personal protective equipment at each centre and also highlight the need to periodically update recommendations as we may need to readopt more restrictive measures de…

medicine.medical_specialtyConsensusEye DiseasesCoronavirus disease 2019 (COVID-19)Control (management)Context (language use)Review ArticleEnfermedades infecciosasEye careeye care03 medical and health sciencesCOVID-19 eye care eye health lockdown easing pandemic personal protective equipment0302 clinical medicineCOVID‐19eye healthSalud públicaEpidemiologyPandemicHealth caremedicineHumansPandemicsReview ArticlesPersonal protective equipmentSARS-CoV-2business.industrypandemicCOVID-19General Medicinemedicine.diseaseTelemedicineVirusOphthalmologyAtenció primàriaSpainCommunicable Disease ControlPractice Guidelines as Topiclockdown easingpersonal protective equipment030221 ophthalmology & optometryUlls Malalties i defectesOftalmologíaMedical emergencybusinessUlls030217 neurology & neurosurgery
researchProduct

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review

2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The latter is a pandemic that has the potential of developing into a severe illness manifesting as systemic inflammatory response syndrome, acute respiratory distress syndrome, multi-organ involvement and shock. In addition, advanced age and male sex and certain underlying health conditions, like type 2 diabetes mellitus (T2DM), predispose to a higher risk of greater COVID-19 severity and mortality. This calls for an urgent identification of antidiabetic agents associated with more favourable COVID-19 outcomes among patients with T2DM, as well as recognition of their potential underlying…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)1 receptor agonists Sodium-glucose co-transporter&nbspEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19 Dipeptidyl peptidase&nbspReviewType 2 diabetesSodium-glucose co-transporter 2 inhibitorsType 2 diabetesGlucagon-like peptide 1 receptor agonistsDiabetes mellitusPandemicInternal Medicinemedicine2 diabetesIntensive care medicineAntidiabetic agents4 inhibitors Glucagon-like peptide&nbspbusiness.industryCOVID-19medicine.diseaseSystemic inflammatory response syndromeShock (circulatory)Dipeptidyl peptidase 4 inhibitorsmedicine.symptombusiness2 inhibitors Type&nbspDiabetes Therapy
researchProduct

Impact of the COVID-19 pandemic on hospitalizations for acute coronary syndromes: a multinational study

2021

Abstract Background COVID-19 has challenged the health system organization requiring a fast reorganization of diagnostic/therapeutic pathways for patients affected by time-dependent diseases such as acute coronary syndromes (ACS). Aim To describe ACS hospitalizations, management, and complication rate before and after the COVID-19 pandemic was declared. Design Ecological retrospective study. Methods: We analyzed aggregated epidemiological data of all patients > 18 years old admitted for ACS in twenty-nine hub cardiac centers from 17 Countries across 4 continents, from December 1st, 2019 to April 15th, 2020. Data from December 2018 to April 2019 were used as historical period. Results…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Adolescent[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyRate ratio03 medical and health sciences0302 clinical medicineInternal medicinePandemicEpidemiologymedicineHumans030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromePandemicsRetrospective StudiesOriginal PaperFramingham Risk Scorebusiness.industrySARS-CoV-2COVID-19Retrospective cohort studyGeneral Medicinemedicine.diseaseConfidence intervalHospitalizationbusinessAcademicSubjects/MED00010
researchProduct

The Influence of Infection and Colonization on Outcomes in Inpatients With COVID-19 : Are We Forgetting Something?

2021

The COVID-19 epidemic has been a great challenge to health systems and especially hospitals. A prospective observational epidemiological study was planned as of February 26, 2020 in a tertiary hospital in the Valencia region. The total number of patients followed up with complete information during the first year was 2,448. Among other variables, the comorbidities of the patients were collected (and grouped in the Charson index), the stay in the intensive care unit (ICU), the co-infections, and the colonizations. Data on nosocomial infections due to said virus were also collected. The median days from the onset of symptoms to diagnosis were 4 + 4.6, while an additional 4.4 days had to pass …

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)COVID epidemiologyMedicina preventivaEpidemiologymedicineHumansrisk factorsColonizationEpidemiologiaOriginal ResearchInpatientsForgettingbusiness.industrySARS-CoV-2Public Health Environmental and Occupational HealthCOVID-19germ colonizationCandida aurismedicine.diseaseComorbiditySalut públicaIntensive Care UnitsCandida aurisdisease managementEmergency medicineCoinfectionObservational studyPublic HealthPublic aspects of medicineRA1-1270business
researchProduct

Thoracic Anesthesia during the 2019 Novel Coronavirus Infection Pandemic: 2021 Updated Recommendations for Airway Management by the EACTAIC Thoracic …

2021

Contains fulltext : 244115.pdf (Publisher’s version ) (Closed access) The novel coronavirus pandemic has radically changed the landscape of normal surgical practice. Lifesaving cancer surgery, however, remains a clinical priority, and there is an increasing need to fully define the optimal oncologic management of patients with varying stages of lung cancer, allowing prioritization of which thoracic procedures should be performed in the current era. Healthcare providers and managers should not ignore the risk of a bimodal peak of mortality in patients with lung cancer; an imminent spike due to mortality from acute coronavirus disease 2019 (COVID-19) infection, and a secondary peak reflecting…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Critical Caremedicine.medical_treatmentcoronavirusThoracic anesthesiaSubspecialtyHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Special ArticleAnesthesiologyAnesthesiologyIntensive carePandemicmedicineHumansAnesthesiaLung cancerPandemicsbusiness.industrySARS-CoV-2COVID-19medicine.diseaseInfectious periodAnesthesiology and Pain MedicineAnesthesialung separationpersonal protective equipmentAirway managementCardiology and Cardiovascular MedicinebusinessJournal of Cardiothoracic and Vascular Anesthesia
researchProduct